Login
Phathom Pharmaceuticals, Inc. logo

Phathom Pharmaceuticals, Inc.

phathompharma.com

What Do They Do?

Sells VOQUEZNA medicines for gastrointestinal conditions, including reflux disease and H. pylori infection, to U.S. patients through healthcare channels.

How Do They Make Money?

Pharmaceutical wholesalers and select pharmacies pay for VOQUEZNA products when the products are delivered; those buyers resell them to pharmacies and healthcare providers.

FY2025 revenue

Who Are Their Customers?

The company sells mainly to pharmaceutical wholesale distributors and select pharmacies, which resell the products to retail pharmacies, institutions, clinics and patients.

Do Revenues Turn Into Profits?

No. It lost $221.2M in FY2025.

Operating income, FY2025
−91% of revenue
▲ +42% (Loss) vs FY2024 (−$277.5M, −502%)
Net income, FY2025
−126% of revenue
▲ +34% (Loss) vs FY2024 (−$334.3M, −605%)
Free cash flow, FY2025
−95% of revenue
▲ +37% (Loss) vs FY2024 (−$266.9M, −483%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +71%
vs $49.5M in Q3 FY2025
Net income
▲ +54% (Loss)
vs −$30M in Q3 FY2025
  • Jul 30, 2026 Phathom lowered its 2026 net revenue guidance. The updated range is $310–325 million, down from the previous $320–345 million.

From development to U.S. sales The older report described Phathom as focused on developing and commercializing treatments, with its products and candidate still in development. The latest report describes an active U.S. business selling VOQUEZNA products and developing further treatments.

Who Do They Compete With?

Competes with Sebela Pharmaceuticals, Daewoong Pharmaceutical, Cinclus Pharma Holding AB, and RedHill Biopharma

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support